PR Newswire PharmaOriginal article
Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
SB-01IDCTPositive
AI Analysis
Summary
The degenerative disc disease market is shifting toward regenerative and disease-modifying therapies, with emerging pipeline candidates including SB-01 and IDCT expected to drive growth at approximately 19% CAGR through 2036.
Importance:3/10
Sentiment:
0.60
degenerative disc diseaseregenerative medicinecell replacement therapyNF-kappa B inhibitorscartilage regenerationmarket analysispipeline candidates
Read the original article
Published by PR Newswire Pharma on July 20, 2026 2:31 PM